Natasha Leighl, MD, MMSc, FRCPC, FASCO - Raising the Bar With Immunotherapy in Early-Stage NSCLC: Insights to Inform Treatment Decisions

What this episode covers

Visit https://www.peervoice.com/XNA860 to view the entire programme with slides. After completing “Natasha Leighl, MD, MMSc, FRCPC, FASCO - Raising the Bar With Immunotherapy in Early-Stage NSCLC: Insights to Inform Treatment Decisions”, participants will be able to: Describe the evidence with immunotherapy-based regimens in resectable early-stage non–small-cell lung cancer (NSCLC); Propose strategies to optimize multidisciplinary collaboration in the care of patients with resectable early-stage NSCLC; and Illustrate the optimal use of immunotherapy-based regimens for patients with resectable early-stage NSCLC.

Distinct summary based on available episode metadata or transcript content.